Relevant bibliographies by topics / Amyloid burden

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Amyloid burden'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Amyloid burden.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Amyloid burden"

1

Choo, IL Han, Ari Chong, Ji Yeon Chung, Jung-Min Ha, Yu Yong Choi, and Hoowon Kim. "A Single Baseline Amyloid Positron Emission Tomography Could Be Sufficient for Predicting Alzheimer’s Disease Conversion in Mild Cognitive Impairment." Psychiatry Investigation 19, no. 5 (2022): 394–400. http://dx.doi.org/10.30773/pi.2022.0014.

Full text
Abstract:
Objective Baseline amyloid burden in mild cognitive impairment (MCI) has been linked to conversion to Alzheimer’s disease (AD), but the comparison of baseline and longitudinal changes in amyloid burden for predicting AD remains unresolved. The objectives of this study aimed to compare the prognostic ability of baseline and longitudinal changes in amyloid burden in MCI patients.Methods Seventy-five individuals with MCI were recruited and examined annually by clinical interviews for a mean follow-up of 24 months (range, 11.6–42.0). [18F]Florbetaben positron emission tomography (PET) scans were p
APA, Harvard, Vancouver, ISO, and other styles
2

Aman, Yahyah. "Amyloid burden across the spectrum." Nature Aging 2, no. 3 (2022): 187. http://dx.doi.org/10.1038/s43587-022-00200-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jackson, Melinda L., Marina Cavuoto, Rachel Schembri, et al. "Severe Obstructive Sleep Apnea Is Associated with Higher Brain Amyloid Burden: A Preliminary PET Imaging Study." Journal of Alzheimer's Disease 78, no. 2 (2020): 611–17. http://dx.doi.org/10.3233/jad-200571.

Full text
Abstract:
Background: Obstructive sleep apnea (OSA) has been linked to an increase risk of dementia. Few studies have cross-sectionally examined whether clinically-confirmed OSA is associated with a higher brain amyloid burden. Objective: The aim of this study was to compare brain amyloid burden in individuals with untreated OSA and healthy controls, and explore associations between amyloid burden and polysomnographic and subjective measures of sleep, demographics, and mood. Methods: Thirty-four individuals with OSA (mean age 57.5±4.1 y; 19 males) and 12 controls (mean age 58.5±4.2 y; 6 males) underwent
APA, Harvard, Vancouver, ISO, and other styles
4

Graff-Radford, Jonathan, Timothy Lesnick, Alejandro A. Rabinstein, et al. "Cerebral microbleed incidence, relationship to amyloid burden." Neurology 94, no. 2 (2019): e190-e199. http://dx.doi.org/10.1212/wnl.0000000000008735.

Full text
Abstract:
ObjectiveTo determine the incidence of cerebral microbleeds (CMBs) and the association of amyloid PET burden with incident CMBs.MethodsA total of 651 participants, age ≥50 years (55% male), underwent 3T MRI scans with ≥2 separate T2*-weighted gradient recalled echo sequences from October 2011 to August 2017. Eighty-seven percent underwent 11C Pittsburgh compound B (PiB) PET scans. Age-specific CMB incidence rates were calculated by using the piecewise exponential model. Using structural equation models (SEMs), we assessed the effect of amyloid load and baseline CMBs on future CMBs after consid
APA, Harvard, Vancouver, ISO, and other styles
5

Villemagne, Victor L., and Christopher C. Rowe. "Amyloid imaging." International Psychogeriatrics 23, S2 (2011): S41—S49. http://dx.doi.org/10.1017/s1041610211000895.

Full text
Abstract:
ABSTRACTMolecular neuroimaging techniques such as PET are proving valuable in the early and differential diagnosis of Alzheimer's disease (AD). With the advent of new therapeutic strategies aimed at reducing β-amyloid (Aβ) burden in the brain to potentially prevent or delay functional and irreversible cognitive loss, there is increased interest in developing agents that allow assessment of Aβ burden in vivo.Amyloid imaging with PET has proven useful in the discrimination of dementias, showing significantly higher Aβ burden in the gray matter of AD patients when compared with healthy controls o
APA, Harvard, Vancouver, ISO, and other styles
6

Verma, A. "Imaging of Amyloid Burden and Distribution in Cerebral Amyloid Angiopathy." Yearbook of Neurology and Neurosurgery 2008 (January 2008): 137–40. http://dx.doi.org/10.1016/s0513-5117(08)79024-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Johnson, Keith A., Matt Gregas, John A. Becker, et al. "Imaging of amyloid burden and distribution in cerebral amyloid angiopathy." Annals of Neurology 62, no. 3 (2007): 229–34. http://dx.doi.org/10.1002/ana.21164.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Graff-Radford, Jonathan, Eider M. Arenaza-Urquijo, David S. Knopman, et al. "White matter hyperintensities: relationship to amyloid and tau burden." Brain 142, no. 8 (2019): 2483–91. http://dx.doi.org/10.1093/brain/awz162.

Full text
Abstract:
Abstract Although white matter hyperintensities have traditionally been viewed as a marker of vascular disease, recent pathology studies have found an association between white matter hyperintensities and Alzheimer’s disease pathologies. The objectives of this study were to investigate the topographic patterns of white matter hyperintensities associated with Alzheimer’s disease biomarkers measured using PET. From the population-based Mayo Clinic Study of Aging, 434 participants without dementia (55% male) with FLAIR and gradient recall echo MRI, tau-PET (AV-1451) and amyloid-PET scans were ide
APA, Harvard, Vancouver, ISO, and other styles
9

Palta, Priya, Brady Rippon, Christiane Reitz, et al. "Apolipoprotein E genotype and in vivo amyloid burden in middle-aged Hispanics." Neurology 95, no. 15 (2020): e2086-e2094. http://dx.doi.org/10.1212/wnl.0000000000010707.

Full text
Abstract:
ObjectiveTo examine in vivo amyloid burden in relation to APOEε4 genotype in middle-aged Hispanics. We hypothesize higher amyloid levels among APOE ε4 carriers vs APOE ε4 noncarriers.MethodsThis is a cross-sectional study in a community-based sample of 249 middle-aged Hispanics in New York City who underwent a 3T brain MRI and PET with the amyloid radioligand 18F-florbetaben. APOE genotype was the primary exposure. The primary outcome was amyloid positivity. The secondary outcome was subthreshold amyloid levels examined as a continuous variable.ResultsAPOE ε4 carriers (n = 85) had a higher fre
APA, Harvard, Vancouver, ISO, and other styles
10

Yun, Chang-Ho, Ho-Young Lee, Seung Ku Lee, et al. "Amyloid Burden in Obstructive Sleep Apnea." Journal of Alzheimer's Disease 59, no. 1 (2017): 21–29. http://dx.doi.org/10.3233/jad-161047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Amyloid burden"

1

Ashton, Nicholas James. "A blood-based signature of neocortical amyloid burden : an early diagnostic population screening tool for Alzheimer's disease." Thesis, King's College London (University of London), 2017. https://kclpure.kcl.ac.uk/portal/en/theses/a-bloodbased-signature-of-neocortical-amyloid-burden(cb20c7b8-c969-469c-b9bf-cdfac3c41415).html.

Full text
Abstract:
Alzheimer´s disease (AD) biomarkers that can detect and track disease progression at its earliest stages to aid the critical search for a disease modifying therapy is much needed. Markers of in vivo amyloid-beta (Aβ) deposition (e.g. 11C-PiB) combined with positron emission tomography (PET) or cerebrospinal fluid (CSF) examination are becoming widely utilised as essential criterion for AD prevention trials. Although necessary, this is likely to come at a great cost and will restrict the progression of some trials. The inexpensive and accessible nature of a blood-based prediction for AD risk wo
APA, Harvard, Vancouver, ISO, and other styles
2

Kohli, Neha. "Amelioration of Amyloid Burden in Advanced Human and Mouse Alzheimer's Disease Brains by Oral Delivery of Myelin Basic Protein Bioencapsulated in Plant Cells." Master's thesis, University of Central Florida, 2012. http://digital.library.ucf.edu/cdm/ref/collection/ETD/id/5380.

Full text
Abstract:
One of the pathological hallmarks of Alzheimer's disease (AD) is the amyloid plaque deposition in aging brains by aggregation of amyloid-? (A?) peptides. In this study, the effect of chloroplast derived myelin basic protein (MBP) fused with cholera toxin subunit B (CTB) was investigated in advanced diseased stage of human and mouse AD brains. The CTB-fusion protein in chloroplasts facilitates transmucosal delivery in the gut by the natural binding ability of CTB pentameric form with GM1 receptors on the intestinal epithelium. Further, bioencapsulation of the MBP within plant cells confers prot
APA, Harvard, Vancouver, ISO, and other styles
3

Burns, Andrew J. "Fear conditioning as a measuring tool for cognitive deficits related to amyloid burden coupled with iron, zinc, and copper in the transgenic Tg2576 mouse model for alzheimer's disease." Fairfax, VA : George Mason University, 2008. http://hdl.handle.net/1920/3004.

Full text
Abstract:
Thesis (M.A.)--George Mason University, 2008.<br>Vita: p. 68. Thesis director: Jane M. Flinn. Submitted in partial fulfillment of the requirements for the degree of Master of Arts in Psychology. Title from PDF t.p. (viewed June 30, 2008). Includes bibliographical references (p. 62-67). Also issued in print.
APA, Harvard, Vancouver, ISO, and other styles
4

McAlpine, Fiona E. "The Role of TNF Singaling in Regulating Beta-Amyloid Burden in the 3xTgAD Mouse Model of Alzheimer's Disease." 2008. http://www4.utsouthwestern.edu/library/ETD/etdDetails.cfm?etdID=372.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sévigny, Dupont Pénélope. "Impact de la charge amyloïde, des lésions de la substance blanche et des changements de la matière grise sur la cognition dans le vieillissement normal." Thesis, 2020. http://hdl.handle.net/1866/25263.

Full text
Abstract:
La prévalence de changements cérébraux pathologiques dans la population âgée est très élevée, même chez des individus en bonne santé et pleinement autonomes. L’accumulation anormale de la protéine bêta-amyloïde (A), un biomarqueur-clé de la maladie d’Alzheimer (MA), et les hypersignaux de la substance blanche (HSB), qui sont des lésions des petits vaisseaux cérébraux de la substance blanche, sont parmi les pathologies cérébrales liées à l’âge les plus répandues. Un ensemble de preuves scientifiques s’appuyant sur des données neuropathologiques, neuropsychologiques et d’imagerie cérébrale sugg
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Amyloid burden"

1

O’Neal, M. Angela. Cognitive Concerns. Edited by Angela O’Neal. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190609917.003.0030.

Full text
Abstract:
This chapter reviews the incidence and gender-specific risks for women developing Alzheimer’s disease, AD. The incidence of AD doubles every five years beginning at age 60. Furthermore, AD is 2–3 times more common in women. Observational trials suggested that estrogen could play a role in delaying the onset of AD. However, the Women’s Health Initiative Memory Study, WHIMS, published in 2003, demonstrated that estrogen, with or without medroxyprogesterone, substantially increased the risk of dementia of any cause, with AD being the most frequent etiology. Additional studies suggesting that ther
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Amyloid burden"

1

Jackson, Melinda L., Marina Cavuoto, Rachel Schembri, et al. "Higher Brain Amyloid Burdens in Patients with Severe Obstructive Sleep Apnea: A Pilot PET Imaging Study." In Handbook of Prevention and Alzheimer’s Disease. IOS Press, 2024. http://dx.doi.org/10.3233/aiad230031.

Full text
Abstract:
Background: Obstructive sleep apnea (OSA) has been linked to an increased risk of dementia. Few studies have cross-sectionally examined whether clinically-confirmed OSA is associated with a higher brain amyloid burden. Objective: This compared brain amyloid burden in individuals with untreated OSA and healthy controls, and explored associations between amyloid burden and polysomnographic and subjective measures of sleep, demographics, and mood. Methods: Thirty-four individuals with OSA (mean age 57.5 ± 4.1 y; 19 males) and 12 controls (mean age 58.5 ± 4.2 y; 6 males) underwent a clinical polys
APA, Harvard, Vancouver, ISO, and other styles
2

Furst Ansgar J. and Lal Rayhan A. "Amyloid-&beta; and Glucose Metabolism in Alzheimer's Disease." In Advances in Alzheimer’s Disease. IOS Press, 2011. https://doi.org/10.3233/978-1-60750-793-2-235.

Full text
Abstract:
This study used PET with the amyloid-&amp;beta; (A&amp;beta;) imaging agent11C Pittsburgh Compound-B (PIB) and the glucose metabolic tracer18F-fluorodeoxyglucose (FDG) to map the relationship of A&amp;beta; deposition to regional glucose metabolism in Alzheimer's disease (AD). Comparison of 13 AD patients&amp;apos; FDG scans with 11 healthy controls confirmed a typical temporo-parietal hypometabolic pattern in AD. In contrast, PIB distribution-volume-ratios showed a distinct pattern of specific tracer retention in fronto-temporo-parietal regions and striatum in AD with peaks in left frontal co
APA, Harvard, Vancouver, ISO, and other styles
3

Donovan Nancy J., Hsu David C., Dagley Alexander S., et al. "Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults." In Advances in Alzheimer’s Disease. IOS Press, 2015. https://doi.org/10.3233/978-1-61499-542-5-205.

Full text
Abstract:
Even low levels of depressive symptoms are associated with an increased risk of cognitive decline in older adults without overt cognitive impairment (CN). Our objective was to examine whether very low, &amp;ldquo;subthreshold symptoms of depression&amp;rdquo; are associated with Alzheimer's disease (AD) biomarkers of neurodegeneration in CN adults and whether these associations are specific to particular depressive symptoms. We analyzed data from 248 community-dwelling CN older adults, including measurements of cortical amyloid burden, neurodegeneration markers of hippocampal volume (HV) and c
APA, Harvard, Vancouver, ISO, and other styles
4

Triumbari, Elizabeth Katherine Anna, Agostino Chiaravalloti, Orazio Schillaci, Nicola Biagio Mercuri, and Claudio Liguori. "Positron Emission Tomography/Computed Tomography Imaging in Therapeutic Clinical Trials in Alzheimer’s Disease: An Overview of the Current State of the Art of Research." In Advances in Alzheimer’s Disease. IOS Press, 2024. https://doi.org/10.3233/aiad240045.

Full text
Abstract:
The integration of positron emission tomography/computed tomography (PET/CT) has revolutionized the landscape of Alzheimer’s disease (AD) research and therapeutic interventions. By combining structural and functional imaging, PET/CT provides a comprehensive understanding of disease pathology and response to treatment assessment. PET/CT, particularly with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG), facilitates the visualization of glucose metabolism in the brain, enabling early diagnosis, staging, and monitoring of neurodegenerative disease progression. The advent of amyloid and tau PET
APA, Harvard, Vancouver, ISO, and other styles
5

Yarns, Brandon, and Aaron Greene. "A picture worth a thousand words." In Geriatric Psychiatry, edited by Marc E. Agronin and Ipsit V. Vahia. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197521670.003.0005.

Full text
Abstract:
Structural imaging is clinically useful for identifying or ruling out non-neurodegenerative causes of cognitive dysfunction, such as vascular pathology, abscesses, and mass lesions. Computed tomography (CT) and magnetic resonance imaging (MRI) are the two main forms of structural imaging. There are several MRI techniques and sequences that can be useful for clarifying potential causes of neurocognitive impairment when there is clinical suspicion. While there are specific patterns of atrophy that are representative of distinct variants of neurodegenerative disease, they are often not diagnostic
APA, Harvard, Vancouver, ISO, and other styles
6

Watt Andrew D., Villemagne Victor L., and Barnham Kevin J. "Metals, Membranes, and Amyloid-&beta; Oligomers: Key Pieces in the Alzheimer's Disease Puzzle?" In Advances in Alzheimer’s Disease. IOS Press, 2013. https://doi.org/10.3233/978-1-61499-154-0-283.

Full text
Abstract:
Over the past 100 years, there has been an exponential increase in our understanding of the underlying pathology of Alzheimer's disease (AD). This growth in knowledge has largely stemmed from the intensification of research into AD which has occurred over the past three decades and the incorporation of the amyloid cascade hypothesis as the generally accepted dogma of AD pathogenesis. While at times contentious, the notion that AD arises from aberrations in amyloid-&amp;beta; (A&amp;beta;) production and degradation has led to a number of significant breakthroughs in the way in which AD is curr
APA, Harvard, Vancouver, ISO, and other styles
7

Villemagne Victor L. and Rowe Christopher C. "Long Night&apos;s Journey into the Day: Amyloid-&beta; Imaging in Alzheimer's Disease." In Advances in Alzheimer’s Disease. IOS Press, 2013. https://doi.org/10.3233/978-1-61499-154-0-349.

Full text
Abstract:
The introduction of radiotracers for the non-invasive in vivo quantification of amyloid-&amp;beta; (A&amp;beta;) burden in the brain has revolutionized the approach to the evaluation of Alzheimer's disease (AD). A&amp;beta; burden as measured by positron emission tomography (PET) matches histopathological reports of A&amp;beta; distribution in aging and dementia. It appears more accurate than FDG for the diagnosis of AD, and is an excellent aid in the differential diagnosis of AD from frontotemporal lobar degeneration. Apolipoprotein E &amp;epsiv;4 carriers, independent of diagnosis or disease
APA, Harvard, Vancouver, ISO, and other styles
8

Barber, Robert. "Clinical biomarkers in the diagnosis of dementia." In Oxford Textbook of Old Age Psychiatry. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198807292.003.0007.

Full text
Abstract:
Biomarkers support clinical practice in almost every area of medicine and are increasingly used in the assessment of brain diseases. Their role in the diagnosis of dementia is covered in this chapter. Structural neuroimaging should be considered in all patients with suspected dementia. Functional imaging offers additional insights into the biological activity of the brain, providing estimates of regional cerebral blood flow, glucose metabolism, dopamine neurotransmission, and amyloid burden. Certain dementias, notably Alzheimer’s disease, also have a characteristic profile of cerebrospinal flu
APA, Harvard, Vancouver, ISO, and other styles
9

Lock, Margaret. "Making and Remaking Alzheimer Disease." In The Alzheimer Conundrum. Princeton University Press, 2013. http://dx.doi.org/10.23943/princeton/9780691149783.003.0002.

Full text
Abstract:
This chapter focuses on the “discovery” of Alzheimer disease (AD) and a somewhat condensed genealogy of its history to the present time. Emphasis is given to the virtual disappearance of AD for over four decades after its initial identification, followed by its rediscovery in the late 1960s in association with government and medical recognition of aging populations and their impending burden on society. The chapter also discusses the consolidation of what has been the dominant research paradigm in AD research for the past four decades-the amyloid cascade hypothesis, grounded in localization th
APA, Harvard, Vancouver, ISO, and other styles
10

Ellajosyula, Ratnavalli. "Early onset Alzheimer’s disease." In Oxford Textbook of Neurologic and Neuropsychiatric Epidemiology, edited by Carol Brayne, Valery L. Feigin, Lenore J. Launer, and Giancarlo Logroscino. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198749493.003.0009.

Full text
Abstract:
The term ‘early onset Alzheimer’s disease’ (EOAD) is used when symptoms of Alzheimer’s disease (AD) occur in patients younger than 65 years. EOAD is an uncommon condition and data on epidemiology is limited. Prevalence rates range from 15 to 200 and incidence rates 2.4–22.6 per 100,000 population. Prevalence rates increase with age similar to that for late onset AD. The prevalence of autosomal dominant EOAD is 5.2 per 100,000. Half of these patients have an underlying mutation in amyloid precursor protein, presenilin 1 or 2 genes. Apolipoprotein E genotype is a risk factor for EOAD and homozyg
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Amyloid burden"

1

Beyer, L., C. Sacher, T. Blume, et al. "Asymmetry of plaque burden in amyloid mouse models." In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708323.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ngan, Esther, Andrew A. Badachhape, Eric Tanifum, Ananth Annapragada, Ketan B. Ghaghada, and Zbigniew Starosolski. "Standardized MR nano-radiomics for early detection and amyloid burden classification in Alzheimer’s disease." In Clinical and Biomedical Imaging, edited by Barjor S. Gimi and Andrzej Krol. SPIE, 2024. http://dx.doi.org/10.1117/12.3008263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ko, Hyunwoong, Taehyeong Kim, Ko Jung-Joon Ihm та Hong-Gee Kim. "Building Cost-effective Model For Predicting β-Amyloid Burden by Combination of Cortical Thickness, Volume, and Neuropsychological Assessment Measures". У 2018 International Conference on Information and Communication Technology Convergence (ICTC). IEEE, 2018. http://dx.doi.org/10.1109/ictc.2018.8539432.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Harrie, Ashley, Benjamin Hampstead, Catherine Lewis, Emily Herreshoff, and Vikas Kotagal. "Amyloid plaque burden and dual tasking impairments on the Timed up and go test in Parkinson disease (P5-11.006)." In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000202293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Studart-Neto, Adalberto, Artur Martins Coutinho, Camila de Godoi Carneiro, et al. "Amyloid burden was associated with worse memory performance but no associated with conversion to mild cognitive impairment in SuperAgers." In Reunião de Pesquisadores em Doença de Alzheimer e Desordens Relacionadas. Academia Brasileira de Neurologia, 2024. http://dx.doi.org/10.22491/19805764/059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bermudez, Camilo, Timothy Lesnick, Swati More, et al. "Optical Coherence Tomography Angiography (OCTA) Retinal Imaging Can Detect Burden of Small Vessel Disease and Amyloid Deposition in the Brain (P11-5.001)." In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000202031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mariano, Luciano, Larissa Salvador, Patrícia Peles, et al. "AT(N) MODEL AND ITS ASSOCIATION WITH NEUROPSYCHOLOGICAL MARKERS." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda019.

Full text
Abstract:
Background: The National Institute on Aging and Alzheimer’s Association (NIA-AA) proposed the AT(N) model to diagnose Alzheimer’s disease (AD) considering some biomarkers: amyloid beta (A), phosphorylated tau (T), and neurodegeneration (N). Still, AT(N) correlation with cognitive markers is not yet covered. Objective: To investigate the neuropsychological profile of patients with CSF biomarkers according to AT(N) classification. Methods: Sixty-five patients with thorough neuropsychological data and results of CSF biomarkers were included in the study. We performed a cluster analysis using biom
APA, Harvard, Vancouver, ISO, and other styles
8

Socher, Karen, Douglas Nunes, Deborah Lopes, et al. "VISUAL MEDIAL TEMPORAL ATROPHY SCALES IN CLINICIAN PRACTICE." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda102.

Full text
Abstract:
Background: Visual atrophy scales from the medial temporal region are auxiliary biomarker methods in Alzheimer’s Disease(AD).They may correlated with progression from preclinical to clinical AD. Objective: We aimed to compare medial temporal lobe atrophy (MTA) and entorhinal cortex atrophy (ERICA) scales for magnetic resonance image as a useful tool for probable AD diagnosis and evaluate their accuracy, sensitivity and specificity, regarding clinical diagnosis and 11C-PIB-PET. Methods: 2 neurologists blinded to diagnosis classified 113 adults (over 65y) through MTA and ERICA scales and correla
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Amyloid burden' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography